Other recurrent molecular alterations, including NF-κB activation, PI3K signaling, microsatellite instability, high tumor mutational burden, and natural killer (NK) cell activation, may further contribute to the efficacy of PD-1 inhibitors in cHL [37,38]. This evidence concerns the gene NFKB1 and classic Hodgkin lymphoma.